957 related articles for article (PubMed ID: 37306737)
21. Prognostic value of programmed cell death ligand 1 (PD-L1) for hepatocellular carcinoma: a meta-analysis.
Li XS; Li JW; Li H; Jiang T
Biosci Rep; 2020 Apr; 40(4):. PubMed ID: 32255189
[TBL] [Abstract][Full Text] [Related]
22. C-X-C chemokine receptor 2 (Cxcr2) promotes hepatocellular carcinoma immune evasion via regulating programmed death-ligand 1 (PD-L1).
Wan Y; Ge K; Zhou W; Lu J; Jia C; Zhu H
Biol Chem; 2021 May; 402(6):729-737. PubMed ID: 33583159
[TBL] [Abstract][Full Text] [Related]
23. Single sample scoring of hepatocellular carcinoma: A study based on data mining.
Zhu D; Wu ZH; Xu L; Yang DL
Int J Immunopathol Pharmacol; 2021; 35():20587384211018389. PubMed ID: 34053310
[TBL] [Abstract][Full Text] [Related]
24. CCL8 as a promising prognostic factor in diffuse large B-cell lymphoma
Lou X; Zhao K; Xu J; Shuai L; Niu H; Cao Z; Wang J; Zhang Y
Front Immunol; 2022; 13():950213. PubMed ID: 36072582
[TBL] [Abstract][Full Text] [Related]
25. Bioinformatics Analysis Identifies
Guo S; Yang Q
Front Biosci (Landmark Ed); 2024 Jan; 29(1):39. PubMed ID: 38287833
[TBL] [Abstract][Full Text] [Related]
26. N6-methyladenosine with immune infiltration and PD-L1 in hepatocellular carcinoma: novel perspective to personalized diagnosis and treatment.
Shi Y; Wang Y; Zhang W; Niu K; Mao X; Feng K; Zhang Y
Front Endocrinol (Lausanne); 2023; 14():1153802. PubMed ID: 37469973
[TBL] [Abstract][Full Text] [Related]
27. LPCAT1 acts as an independent prognostic biomarker correlated with immune infiltration in hepatocellular carcinoma.
Li L; Wang X; Ding Y; Hui N; Su B; Yang M
Eur J Med Res; 2022 Oct; 27(1):216. PubMed ID: 36307879
[TBL] [Abstract][Full Text] [Related]
28. PD-L1-Mediated Immunosuppression in Hepatocellular Carcinoma: Relationship with Macrophages Infiltration and Inflammatory Response Activity.
Guo S; Wang X; Zhou H; Gao Y; Wang P; Zhi H; Sun Y; Zhang Y; Gan J; Xiao Y; Ning S
Biomolecules; 2022 Sep; 12(9):. PubMed ID: 36139065
[TBL] [Abstract][Full Text] [Related]
29. Knockdown of METTL5 inhibits the Myc pathway to downregulate PD-L1 expression and inhibits immune escape of hepatocellular carcinoma cells.
Xu W; Liu S; Zhang G; Liu J; Cao G
J Chemother; 2023 Sep; 35(5):455-464. PubMed ID: 36369791
[TBL] [Abstract][Full Text] [Related]
30. TP53/mTORC1-mediated bidirectional regulation of PD-L1 modulates immune evasion in hepatocellular carcinoma.
Yu J; Ling S; Hong J; Zhang L; Zhou W; Yin L; Xu S; Que Q; Wu Y; Zhan Q; Bao J; Xu N; Liu Y; Chen K; Wei X; Liu Z; Feng T; Zhou L; Xie H; Wang S; Liu J; Zheng S; Xu X
J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 38030304
[TBL] [Abstract][Full Text] [Related]
31. Expression of Programmed Cell Death-Ligands in Hepatocellular Carcinoma: Correlation With Immune Microenvironment and Survival Outcomes.
Liao H; Chen W; Dai Y; Richardson JJ; Guo J; Yuan K; Zeng Y; Xie K
Front Oncol; 2019; 9():883. PubMed ID: 31572677
[TBL] [Abstract][Full Text] [Related]
32. PD-L1
Zhou L; Wang J; Lyu SC; Pan LC; Shi XJ; Du GS; He Q
Technol Cancer Res Treat; 2021; 20():15330338211045820. PubMed ID: 34605709
[No Abstract] [Full Text] [Related]
33. Orphan nuclear receptor TLX promotes immunosuppression via its transcriptional activation of PD-L1 in glioma.
Zhou J; Pei X; Yang Y; Wang Z; Gao W; Ye R; Zhang X; Liu J; Liu Z; Yang X; Tao J; Gu C; Hu W; Chan FL; Li X; Mao J; Wu D
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33858847
[TBL] [Abstract][Full Text] [Related]
34. Tumor-associated macrophages (TAMs)-derived osteopontin (OPN) upregulates PD-L1 expression and predicts poor prognosis in non-small cell lung cancer (NSCLC).
Li Y; Liu H; Zhao Y; Yue D; Chen C; Li C; Zhang Z; Wang C
Thorac Cancer; 2021 Oct; 12(20):2698-2709. PubMed ID: 34423566
[TBL] [Abstract][Full Text] [Related]
35. Genomic stratification based on microenvironment immune types and PD-L1 for tailoring therapeutic strategies in bladder cancer.
Lyu X; Wang P; Qiao Q; Jiang Y
BMC Cancer; 2021 May; 21(1):646. PubMed ID: 34059019
[TBL] [Abstract][Full Text] [Related]
36. Identification of Rad51 as a prognostic biomarker correlated with immune infiltration in hepatocellular carcinoma.
Xu H; Xiong C; Chen Y; Zhang C; Bai D
Bioengineered; 2021 Dec; 12(1):2664-2675. PubMed ID: 34115569
[TBL] [Abstract][Full Text] [Related]
37. Overexpression of PD-L1 and PD-L2 Is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma.
Jung HI; Jeong D; Ji S; Ahn TS; Bae SH; Chin S; Chung JC; Kim HC; Lee MS; Baek MJ
Cancer Res Treat; 2017 Jan; 49(1):246-254. PubMed ID: 27456947
[TBL] [Abstract][Full Text] [Related]
38. Pre-treatment serum levels of soluble programmed cell death-ligand 1 predict prognosis in patients with hepatitis B-related hepatocellular carcinoma.
Han X; Gu YK; Li SL; Chen H; Chen MS; Cai QQ; Deng HX; Zuo MX; Huang JH
J Cancer Res Clin Oncol; 2019 Feb; 145(2):303-312. PubMed ID: 30267213
[TBL] [Abstract][Full Text] [Related]
39. KDM1A Promotes Immunosuppression in Hepatocellular Carcinoma by Regulating PD-L1 through Demethylating MEF2D.
Wang Y; Cao K
J Immunol Res; 2021; 2021():9965099. PubMed ID: 34307695
[TBL] [Abstract][Full Text] [Related]
40. Oncolytic herpesvirus expressing PD-L1 BiTE for cancer therapy: exploiting tumor immune suppression as an opportunity for targeted immunotherapy.
Khalique H; Baugh R; Dyer A; Scott EM; Frost S; Larkin S; Lei-Rossmann J; Seymour LW
J Immunother Cancer; 2021 Mar; 9(4):. PubMed ID: 33820820
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]